Life Sciences

Life Sciences Law360 provides breaking legal news and analysis on the pharmaceutical and medical device industry. Coverage includes high-stakes litigation and policy developments that affect life sciences companies, as well as licensing deals, mergers, and other corporate transactions.



Sign up for a 7-day FREE trial today!



Latest News in Life Sciences

  • March 11, 2026

    DNA Testing Co. Can't Shake Suit Over Genetic Data Sharing

    A Massachusetts federal judge refused to release Nebula Genomics Inc. from a proposed class action accusing it of illegally sharing its customers' genetic information with Meta and other third parties through online tracking tools, finding that the parties' choice-of-law agreement didn't extend to the plaintiff's genetic privacy allegation. 

  • March 11, 2026

    Eli Lilly Ordered To Arbitrate Alzheimer's Drug Feud

    An Illinois federal judge ordered Eli Lilly and Co. on Tuesday to arbitrate a dispute over millions of dollars in milestone payments allegedly owed under a collaboration agreement to develop an Alzheimer's disease drug, ruling that the drugmaker lacked standing to challenge an underlying security agreement.

  • March 11, 2026

    New Wyoming Abortion Law Faces Familiar Legal Challenge

    Just a day after it was signed into law, Wyoming's new anti-abortion law triggered a legal challenge from the same health clinic that successfully sued over the state's previous abortion limits.

  • March 11, 2026

    La. Fights Dismissal Bid In Abortion Regulation Dispute

    The state of Louisiana urged a federal court to deny motions by GenBioPro Inc. and Danco Laboratories seeking dismissal of its suit challenging federal regulation on mail-order abortion drugs, arguing it has established harms stemming from the regulations.

  • March 11, 2026

    Insulin Makers Ask Justices To Review Collusion Case

    Sanofi-Aventis US, Eli Lilly & Co., Novo Nordisk Inc. and AstraZeneca Pharmaceuticals LP have told the U.S. Supreme Court that a ruling reviving a case over insulin drug costs undermines key rules meant to weed out improper antitrust claims.

See more Life Sciences news

Life Sciences

Areas of Coverage

  • AGENCIES
  • U.S. Consumer Product Safety Commission
  • U.S. Food and Drug Administration
  • U.S. Patent and Trademark Office
  • U.S. International Trade Commission
  • POLICY & REGULATION
  • Affordable Care Act
  • Federal Food, Drug, and Cosmetic Act
  • Antitrust and consumer protection controls
  • Drug and medical device lobbying
  • State and international life sciences legislation and regulation
  • ENFORCEMENT
  • Drug and medical device recalls
  • Drug safety actions
  • Pay-for-delay investigations
  • Merger reviews
  • LITIGATION
  • Patent disputes, including
  • Abbreviated New Drug Application litigation
  • Section 301 cases
  • Product safety suits over drugs and medical devices, including off-label marketing and failure-to-warn claims
  • Consumer litigation and class actions
  • Fraud and compliance suits
  • Antitrust disputes
  • Labor and employment suits
  • Shareholder and corporate governance disputes
  • Bankruptcy proceedings
  • TRANSACTIONS
  • Mergers, acquisitions, and joint ventures
  • Share buybacks and stock splits
  • Private equity deals
  • Patent-licensing agreements
  • PROFILES
  • Personnel moves
  • Profiles of life sciences practice groups

Readership

  • Life sciences lawyers at top law firms
  • Corporate counsel and compliance officers at Fortune 1000 companies
  • Executives and attorneys in the drug, biotechnology, and medical device industries
  • Information experts at law firms, agencies, and companies
  • Policymakers at federal and state agencies
  • Judges and court staff across the U.S.
  • Professors, students, and library staff at every accredited law school in the U.S.
  • Attorney and law firm marketing professionals